Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy

Published on 10 July 2024

SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) — Tr1X, Inc. (pronounced “Trix”), a biopharmaceutical company developing engineered Treg and CAR-Treg cell therapies, announced the successful dosing of the first patient in the company’s TRX103-01 proof of concept trial for prevention of Graft versus Host Disease (GvHD) and improved outcomes in patients with hematologic malignancies undergoing mismatched hematopoietic stem cell transplantation (HSCT).

Explore posts connected to this topic

Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD

In a clinical first, Tr1X Bio showed immune reconstitution and engraftment for allogeneic Tr1 cell therapy, establishing clinical safety and...

Interviews

February 11, 2026

Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103

First clinical data from Phase 1 dose-escalation study in patients

Press Releases

February 4, 2026

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing

Videos

November 14, 2025

In a clinical first, Tr1X Bio showed immune reconstitution and

Interviews

February 11, 2026